Changes in serum total IgE, FeNO, and pre-BD FEV<sub>1</sub>%predicted (all <i>p <</i> 0.05) were greater in the non-ACO-A group than in the ACO-A group.<h4>Conclusion</h4>Our findings demonstrate that the Th2-high inflammatory endotype, rather than the ACO diagnostic label, is the primary predictor of omalizumab response. Here, IGHE is linked to Behcet disease.